柳叶刀·Oncology-2012-May

柳叶刀_Oncology-2012-May.pdfReview Phase2trialdesigninneuro-oncologyrevisited:areport fromtheRANOgroup Evanthia Galanis, Wenting Wu, Timothy Cloughesy, Kathleen Lamborn, Bhupinder Mann, Patrick Y Wen, David A Reardon, Wolfgang Wick, David Macdonald, Terri S Armstrong, Michael Weller, Michael Vogelbaum, Howard Colman, Daniel JReview These inherent complexities are emphasised by the high discordance rate between independent reviewers assessing Bevacizumab Bevacizumab+irinotecan radiographic response or progression in patients with(308 scans)(339 scans) recurrent gliomas given bevacizumab²(table 2), and has Rl agrees wiReview could not be assessed on the basis of findings from the Applicability in neuro-oncology trials AVF37089/BRAIN trial, because of the non-comparative A screening design is appropriate when testing the nature of the trial s design.
———— 文字由OCR识别(未校验)，可能存在错字；请以原始完整版为准。